Condition:   Relapsing Remitting Multiple Sclerosis
Interventions:   Drug: natalizumab;   Drug: interferon beta 1-a;   Drug: methylprednisolone;   Other: IV placebo;   Drug: glatiramer acetate
Sponsors:   Biogen Idec;   Elan Pharmaceuticals
Not yet recruiting - verified February 2010

Condition:   Purpura, Thrombocytopenic, Idiopathic
Interventions:   Drug: Eltrombopag;   Drug: Eltrombopag
Sponsor:   GlaxoSmithKline
Recruiting - verified February 2010

Condition:   Renal Cell Carcinoma
Intervention:   Drug: Sunitinib and Dalteparin mono and combination therapy
Sponsors:   Roswell Park Cancer Institute;   Pfizer
Recruiting - verified March 2010

Condition:   Renal Cell Carcinoma
Intervention:   Drug: Aldesleukin
Sponsor:   Roswell Park Cancer Institute
Recruiting - verified March 2010

Condition:   Infection, Human Immunodeficiency Virus
Interventions:   Drug: GSK2248761 formulation 3;   Drug: GSK2248761 formulation 1;   Drug: GSK2248761 reference formulation;   Drug: GSK2248761 formulation 2 or 4
Sponsor:   GlaxoSmithKline
Recruiting - verified February 2010

Condition:   Hodgkin Lymphoma
Intervention:   Drug: Everolimus (RAD001)
Sponsor:   Novartis
Recruiting - verified March 2010

Condition:   Leukemia
Intervention:   Other: laboratory biomarker analysis
Sponsors:   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Prostate Cancer
Intervention:   Procedure: Prostatectomy
Sponsor:   Roswell Park Cancer Institute
Not yet recruiting - verified March 2010

Condition:   Chronic Lymphocytic Leukemia
Intervention:   Drug: Lenalidomide
Sponsors:   Roswell Park Cancer Institute;   Celgene Corporation
Recruiting - verified March 2010

Condition:   Colorectal Cancer
Intervention:   Drug: cetuximab with irinotecan
Sponsor:   Roswell Park Cancer Institute
Recruiting - verified February 2010

Conditions:   Acute Coronary Syndrome;   Atherosclerosis;   Cardiovascular Disease;   Coronary Heart Disease
Interventions:   Drug: Darapladib 160 mg;   Drug: Placebo
Sponsor:   GlaxoSmithKline
Recruiting - verified March 2010

Condition:   Type 1 Diabetes Mellitus
Interventions:   Drug: INSULIN GLARGINE (HOE901);   Drug: Neutral Protamine Hagedorn (NPH) insulin
Sponsor:   Sanofi-Aventis
Recruiting - verified February 2010

Condition:   Cancer
Intervention:   Drug: TL32711
Sponsor:   TetraLogic Pharmaceuticals
Recruiting - verified February 2010

Condition:   Acute Myeloid Leukemia
Intervention:   Drug: Compound AC220
Sponsor:   Ambit Biosciences Corporation
Recruiting - verified March 2010

Condition:   Metastatic Pancreatic Cancer
Intervention:   Drug: Sorafenib and Everolimus
Sponsors:   Roswell Park Cancer Institute;   Novartis;   Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma
Recruiting - verified March 2010

Condition:   Liver Cancer
Interventions:   Drug: cisplatin;   Drug: doxorubicin hydrochloride;   Drug: fluorouracil;   Drug: irinotecan hydrochloride;   Drug: vincristine sulfate;   Procedure: liver transplantation;   Procedure: therapeutic conventional surgery
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Castration-Resistant Prostate Cancer
Interventions:   Drug: MDV3100;   Drug: Placebo
Sponsor:   Medivation, Inc.
Recruiting - verified March 2010

Condition:   Gastroesophageal Reflux
Interventions:   Drug: Rabeprazole sodium capsules;   Drug: placebo;   Drug: Rabeprazole sodium capsules
Sponsors:   Johnson & Johnson Pharmaceutical Research & Development, L.L.C.;   Eisai Inc.
Recruiting - verified February 2010

Condition:   Lung Cancer
Intervention:   Radiation: stereotactic body radiation therapy
Sponsors:   Radiation Therapy Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Prostate Cancer
Interventions:   Drug: TOK-001;   Drug: TOK-001;   Drug: TOK-001
Sponsor:   Tokai Pharmaceuticals
Recruiting - verified February 2010

Conditions:   Seasonal Influenza;   Cough;   Sore Throat;   Nasal Congestion;   Myalgia;   Headache;   Fatigue
Interventions:   Drug: Peramivir;   Drug: Peramivir
Sponsors:   BioCryst Pharmaceuticals;   Department of Health and Human Services
Recruiting - verified March 2010

Condition:   Subjective Tinnitus
Interventions:   Drug: Neramexane mesylate;   Drug: Placebo
Sponsor:   Merz Pharmaceuticals GmbH
Recruiting - verified March 2010

Condition:   Gaucher Disease, Type 1
Intervention:   Drug: velaglucerase alfa
Sponsor:   Shire Human Genetic Therapies, Inc.
Available - verified March 2010

Conditions:   Fallopian Tube Cancer;   Ovarian Cancer;   Peritoneal Cavity Cancer
Interventions:   Biological: bevacizumab;   Drug: carboplatin;   Drug: cisplatin;   Drug: paclitaxel
Sponsors:   Gynecologic Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Alzheimer's Disease
Intervention:   Drug: Dimebon
Sponsors:   Pfizer;   Medivation, Inc.
Recruiting - verified March 2010

Condition:   Degenerative Disc Disease
Intervention:   Device: NUBAC™
Sponsor:   Pioneer Surgical Technology, Inc.
Recruiting - verified February 2010

Condition:   Metastatic Colorectal Cancer
Intervention:   Drug: EZN-2208, Cetuximab and Irinotecan
Sponsor:   Enzon Pharmaceuticals, Inc.
Recruiting - verified March 2010

Condition:   Cancer
Intervention:   Drug: PF-04691502
Sponsor:   Pfizer
Recruiting - verified February 2010

Condition:   Degenerative Disc Disease
Interventions:   Device: XL TDR;   Other: Lumbar fusion surgery
Sponsor:   NuVasive
Recruiting - verified February 2010

Condition:   Prostate Cancer
Interventions:   Drug: abiraterone acetate plus leuprolide acetate plus prednisone;   Drug: leuprolide acetate
Sponsor:   Cougar Biotechnology, Inc.
Recruiting - verified March 2010

Condition:   Brain and Central Nervous System Tumors
Intervention:   Other: biologic sample preservation procedure
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Chordoma;   Desmoid Tumor;   Sarcoma
Interventions:   Genetic: reverse transcriptase-polymerase chain reaction;   Other: biologic sample preservation procedure;   Other: laboratory biomarker analysis
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Diabetic Nephropathy;   Chronic Kidney Disease
Interventions:   Drug: Placebo for Atrasentan 0,2 mg/mL solution;   Drug: 0.25 mg Atrasentan QD;   Drug: 0.75 mg Atrasentan QD;   Drug: 1.75 mg Atrasentan QD
Sponsor:   Abbott
Recruiting - verified January 2010

Condition:   Neuroblastoma
Interventions:   Genetic: loss of heterozygosity analysis;   Other: cytology specimen collection procedure;   Procedure: biopsy
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Pulmonary Arterial Hypertension
Intervention:   Drug: Commercial Ventavis® (iloprost)
Sponsor:   Actelion
Recruiting - verified March 2010

Condition:   Carcinoma, Hepatocellular
Interventions:   Drug: Sorafenib (Nexavar, BAY43-9006);   Drug: Sorafenib (Nexavar, BAY43-9006) + Erlotinib, Tarceva
Sponsors:   Bayer;   Onyx Pharmaceuticals;   OSI Pharmaceuticals;   Hoffmann-La Roche
Recruiting - verified March 2010

Conditions:   Leukemia;   Lymphoma;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases
Intervention:   Other: biologic sample preservation procedure
Sponsors:   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Lymphoma
Intervention:   Other: biologic sample preservation procedure
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Lung Cancer
Intervention:   Other: biologic sample preservation procedure
Sponsors:   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Sarcoma
Interventions:   Other: biologic sample preservation procedure;   Other: medical chart review
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Leukemia
Interventions:   Genetic: DNA analysis;   Genetic: DNA methylation analysis;   Genetic: gene expression analysis;   Genetic: mutation analysis;   Genetic: polymerase chain reaction;   Genetic: reverse transcriptase-polymerase chain reaction;   Other: high performance liquid chromatography;   Other: laboratory biomarker analysis
Sponsors:   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Head and Neck Cancer
Interventions:   Other: biologic sample preservation procedure;   Procedure: biopsy
Sponsors:   Radiation Therapy Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Sarcoma
Intervention:   Other: biologic sample preservation procedure
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Kidney Cancer;   Nonneoplastic Condition
Interventions:   Genetic: loss of heterozygosity analysis;   Genetic: polymerase chain reaction;   Genetic: polymorphism analysis;   Other: immunohistochemistry staining method;   Procedure: computed tomography;   Procedure: magnetic resonance imaging
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Leukemia;   Lymphoma
Intervention:   Other: biologic sample preservation procedure
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Euvolemic Hyponatremia
Interventions:   Drug: Lixivaptan;   Drug: Placebo
Sponsors:   CardioKine Inc.;   Cardiokine Biopharma, LLC;   Biogen Idec
Recruiting - verified February 2010

Conditions:   Breast Cancer;   Metastatic Cancer;   Multiple Myeloma and Plasma Cell Neoplasm;   Musculoskeletal Complications;   Pain;   Prostate Cancer;   Urinary Complications
Intervention:   Drug: zoledronic acid
Sponsors:   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Breast Cancer
Interventions:   Biological: bevacizumab;   Drug: carboplatin;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: paclitaxel
Sponsors:   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Optic Neuritis
Interventions:   Drug: Glatiramer Acetate (Copaxone);   Drug: placebo
Sponsor:   Teva Pharmaceutical Industries
Recruiting - verified February 2010

Conditions:   Non-small Cell Lung Cancer;   Anemia;   Cancer;   Lung Cancer
Interventions:   Drug: darbepoetin alfa 500 mcg Q3W;   Drug: placebo
Sponsor:   Amgen
Recruiting - verified March 2010

Conditions:   Chronic Myeloproliferative Disorders;   Fanconi Anemia;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases;   Nonmalignant Neoplasm;   Paroxysmal Nocturnal Hemoglobinuria
Interventions:   Biological: anti-thymocyte globulin;   Biological: graft-versus-tumor induction therapy;   Drug: fludarabine phosphate;   Drug: melphalan;   Procedure: allogeneic hematopoietic stem cell transplantation;   Radiation: total-body irradiation
Sponsors:   Roswell Park Cancer Institute;   National Cancer Institute (NCI)
Recruiting - verified November 2009

Condition:   Aspergillosis
Intervention:   Other: No Intervention
Sponsor:   Merck
Recruiting - verified March 2010

Condition:   Metastatic Pancreatic Cancer
Interventions:   Drug: ABI-007/Gemcitabine;   Drug: Gemcitabine
Sponsor:   Abraxis BioScience Inc.
Recruiting - verified December 2009

Condition:   Refractory Hematologic Cancer
Interventions:   Drug: Cdc7-inhibitor (BMS-863233);   Drug: Cdc7-inhibitor (BMS-863233)
Sponsors:   Bristol-Myers Squibb;   Exelixis
Recruiting - verified October 2009

Condition:   Acute Coronary Syndrome
Interventions:   Drug: Apixaban;   Drug: Placebo
Sponsors:   Bristol-Myers Squibb;   Pfizer;   Duke University
Recruiting - verified October 2009

Condition:   Smoking Cessation
Interventions:   Drug: varenicline;   Drug: placebo
Sponsors:   Roswell Park Cancer Institute;   Pfizer
Recruiting - verified March 2010

Condition:   Multiple Sclerosis
Intervention:   Other: Single-Use Autoinjector with a Pre-Filled Liquid Avonex Syringe
Sponsor:   Biogen Idec
Recruiting - verified February 2010

Conditions:   Acute Coronary Syndrome;   Myocardial Infarction;   Myocardial Ischemia;   Unstable Angina
Intervention:   Drug: Rivaroxaban; Placebo
Sponsors:   Johnson & Johnson Pharmaceutical Research & Development, L.L.C.;   Bayer
Recruiting - verified February 2010

Conditions:   Endometrial Cancer;   Fatigue;   Neurotoxicity
Interventions:   Drug: carboplatin;   Drug: paclitaxel;   Radiation: brachytherapy;   Radiation: intensity-modulated radiation therapy;   Radiation: radiation therapy
Sponsors:   Gynecologic Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Rheumatoid Arthritis
Interventions:   Drug: infliximab;   Drug: methotrexate;   Drug: methylprednisolone;   Drug: ocrelizumab;   Drug: sham
Sponsor:   Genentech
Recruiting - verified February 2010

Conditions:   Atherosclerosis;   Cardiovascular Disease;   Coronary Heart Disease;   CV Risk
Interventions:   Drug: Darapladib;   Drug: Placebo
Sponsor:   GlaxoSmithKline
Recruiting - verified March 2010

Condition:   Lung Cancer
Interventions:   Biological: bevacizumab;   Drug: carboplatin;   Drug: pemetrexed disodium;   Genetic: gene expression analysis;   Genetic: polymorphism analysis;   Genetic: protein expression analysis;   Other: laboratory biomarker analysis;   Other: pharmacogenomic studies;   Procedure: quality-of-life assessment
Sponsors:   North Central Cancer Treatment Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Cancer;   Solid Tumors
Interventions:   Drug: Lapatinib in combination with an anti-cancer agent;   Drug: Lapatinib;   Drug: Lapatinib in combination with an anti-cancer agent as specified by parent protocol
Sponsor:   GlaxoSmithKline
Recruiting - verified February 2010

Conditions:   Colon Cancer;   Colorectal Cancer;   Rectal Cancer;   Metastatic Colorectal Cancer
Interventions:   Drug: Panitumumab;   Drug: Bevacizumab;   Drug: mFOLFOX6
Sponsor:   Amgen
Recruiting - verified March 2010

Condition:   Breast Cancer
Interventions:   Biological: bevacizumab;   Drug: ixabepilone;   Drug: paclitaxel;   Drug: paclitaxel albumin-stabilized nanoparticle formulation
Sponsors:   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Advanced Breast Cancer;   Breast Cancer
Interventions:   Drug: Neratinib;   Drug: Lapatinib plus Capecitabine
Sponsor:   Wyeth
Recruiting - verified February 2010

Conditions:   Brain and Central Nervous System Tumors;   Chemotherapeutic Agent Toxicity;   Cognitive/Functional Effects;   Neurotoxicity;   Psychosocial Effects of Cancer and Its Treatment;   Radiation Toxicity;   Therapy-related Toxicity
Interventions:   Other: questionnaire administration;   Procedure: cognitive assessment;   Procedure: psychosocial assessment and care;   Procedure: quality-of-life assessment
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Breast Cancer
Interventions:   Biological: trastuzumab;   Drug: lapatinib ditosylate;   Drug: paclitaxel
Sponsors:   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Breast Cancer
Interventions:   Biological: trastuzumab;   Radiation: radiation therapy
Sponsors:   National Surgical Adjuvant Breast and Bowel Project (NSABP);   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Hemophilia B
Interventions:   Biological: IB1001 (On-Demand);   Biological: IB1001 (Prophylaxis)
Sponsor:   Inspiration Biopharmaceuticals, Inc.
Recruiting - verified February 2010

Condition:   Melanoma
Interventions:   Biological: OncoVEXGM-CSF;   Biological: GM-CSF
Sponsor:   BioVex Limited
Recruiting - verified March 2010

Condition:   Multiple Sclerosis
Interventions:   Drug: Duloxetine HCI;   Drug: Placebo
Sponsor:   Eli Lilly and Company
Recruiting - verified February 2010

Condition:   Lung Cancer
Intervention:   Radiation: stereotactic body radiation therapy
Sponsors:   Radiation Therapy Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Prostatic Neoplasms
Interventions:   Drug: placebo + docetaxel/prednisone;   Drug: dasatinib + docetaxel/prednisone
Sponsor:   Bristol-Myers Squibb
Recruiting - verified October 2009

Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Long-term Effects Secondary to Cancer Therapy in Children;   Lymphoma;   Lymphoproliferative Disorder;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases;   Precancerous Condition;   Unspecified Childhood Solid Tumor, Protocol Specific
Interventions:   Other: survey administration;   Procedure: assessment of therapy complications;   Procedure: long-term screening;   Procedure: study of high risk factors
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Carcinoma, Non-small Cell;   Neoplasm Metastasis
Intervention:   Drug: PF-00299804
Sponsor:   Pfizer
Recruiting - verified March 2010

Condition:   Advanced Malignant Solid Tumors
Intervention:   Drug: PF-00299804
Sponsors:   Pfizer;   Roswell Park Cancer Institute;   South Texas Accelerated Research Therapeutics (START)
Recruiting - verified March 2010

Condition:   Locally Advanced and/or Metastatic Renal Cell Carcinoma
Interventions:   Drug: Sunitinib;   Drug: Pazopanib
Sponsor:   GlaxoSmithKline
Recruiting - verified March 2010

Condition:   Head and Neck Cancer
Interventions:   Drug: cisplatin;   Drug: vandetanib;   Radiation: radiation therapy
Sponsors:   Radiation Therapy Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Secondary Acute Myeloid Leukemia (Secondary AML, sAML)
Interventions:   Drug: Daunorubicin and Cytarabine;   Drug: Amonafide and Cytarabine
Sponsor:   Antisoma Research
Recruiting - verified February 2010

Conditions:   Carcinoma, Large Cell;   Carcinoma, Non-Small-Cell Lung;   Carcinoma, Squamous Cell;   Carcinoma, Adenosquamous Cell
Interventions:   Drug: CP 751,871 (Figitumumab) and Erlotinib;   Drug: Erlotinib
Sponsor:   Pfizer
Recruiting - verified February 2010

Conditions:   Myelofibrosis;   Idiopathic Myelofibrosis;   Essential Thrombocythemia;   Polycythemia Vera
Intervention:  
Sponsor:   Myeloproliferative Disorders-Research Consortium
Recruiting - verified February 2010

Condition:   Human Immunodeficiency Virus
Interventions:   Drug: Maraviroc along with an optimized background antiretroviral drug regimen;   Drug: Optimized background antiretroviral drug regimen without maraviroc
Sponsor:   Pfizer
Recruiting - verified March 2010

Conditions:   Breast Cancer;   Cognitive/Functional Effects;   Fatigue;   Psychosocial Effects of Cancer and Its Treatment;   Sleep Disorders
Interventions:   Procedure: assessment of therapy complications;   Procedure: cognitive assessment;   Procedure: fatigue assessment and management;   Procedure: psychosocial assessment and care
Sponsors:   International Breast Cancer Study Group;   National Cancer Institute (NCI);   Australian New Zealand Breast Cancer Trials Group;   Cancer and Leukemia Group B
Recruiting - verified March 2010

Condition:   Coronary Heart Disease
Interventions:   Drug: dalcetrapib;   Drug: Placebo;   Drug: Evidence-based medical care for Acute Coronary Syndrome
Sponsor:   Hoffmann-La Roche
Recruiting - verified March 2010

Condition:   Leukemia
Interventions:   Drug: cytarabine;   Drug: daunorubicin hydrochloride;   Drug: midostaurin;   Other: placebo
Sponsors:   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Venous Thrombosis
Interventions:   Drug: Enoxaparin;   Drug: warfarin;   Drug: Placebo for apixaban;   Drug: Placebo for enoxaparin;   Drug: Placebo for warfarin;   Drug: apixaban
Sponsors:   Bristol-Myers Squibb;   Pfizer
Recruiting - verified October 2009

Condition:   Lung Cancer
Interventions:   Radiation: 3-dimensional conformal radiation therapy;   Radiation: intensity-modulated radiation therapy
Sponsors:   Cancer and Leukemia Group B;   National Cancer Institute (NCI);   Radiation Therapy Oncology Group
Recruiting - verified March 2010

Condition:   Venous Thrombosis
Interventions:   Drug: Apixaban;   Drug: Placebo
Sponsors:   Bristol-Myers Squibb;   Pfizer
Recruiting - verified February 2010

Condition:   Breast Cancer
Interventions:   Drug: Anastrozole;   Dietary Supplement: flaxseed;   Drug: Placebo
Sponsors:   Roswell Park Cancer Institute;   National Center for Complementary and Alternative Medicine (NCCAM);   AstraZeneca
Recruiting - verified February 2010

Condition:   Infrarenal Abdominal Aortic Aneurysm
Intervention:   Device: Anaconda Stent Graft System
Sponsors:   Terumo CVS;   Vascutek Ltd., Scotland
Recruiting - verified March 2010

Condition:   Sepsis
Interventions:   Drug: Drotrecogin alfa (activated);   Drug: Placebo
Sponsor:   Eli Lilly and Company
Recruiting - verified February 2010

Conditions:   Crohn's Disease;   Ulcerative Colitis;   Inflammatory Bowel Diseases
Interventions:   Biological: infliximab;   Drug: conventional systemic agents;   Biological: Biological therapies other than infliximab
Sponsor:   Centocor Ortho Biotech Services, L.L.C.
Recruiting - verified March 2010

Condition:   Multiple Myeloma and Plasma Cell Neoplasm
Interventions:   Drug: lenalidomide;   Drug: melphalan;   Drug: prednisone;   Drug: thalidomide
Sponsors:   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Pancreatic Cancer
Intervention:   Biological: IMMU-107 (hPAM4)
Sponsor:   Immunomedics, Inc.
Recruiting - verified February 2010

Conditions:   Pneumonia;   Pneumonia, Bacterial
Interventions:   Drug: doripenem;   Drug: imipenem/cilastatin
Sponsor:   Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified February 2010

Condition:   Myelofibrosis
Intervention:   Drug: Fludarabine, Melphalan +/- ATG
Sponsor:   Myeloproliferative Disorders-Research Consortium
Recruiting - verified February 2010

Condition:   Neuroendocrine Carcinoma
Interventions:   Biological: bevacizumab;   Biological: recombinant interferon alfa-2b;   Drug: octreotide acetate
Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Prostate Cancer
Interventions:   Drug: bicalutamide;   Drug: flutamide;   Radiation: radiation therapy
Sponsors:   Radiation Therapy Oncology Group;   National Cancer Institute (NCI);   Cancer and Leukemia Group B
Recruiting - verified March 2010

Conditions:   Cognitive/Functional Effects;   Metastatic Cancer;   Neurotoxicity;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions:   Drug: memantine hydrochloride;   Other: placebo;   Radiation: radiation therapy
Sponsors:   Radiation Therapy Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Leukemia
Interventions:   Drug: cyclophosphamide;   Drug: cytarabine;   Drug: daunorubicin hydrochloride;   Drug: dexamethasone;   Drug: doxorubicin hydrochloride;   Drug: mercaptopurine;   Drug: methotrexate;   Drug: pegaspargase;   Drug: thioguanine;   Drug: vincristine sulfate;   Radiation: radiation therapy
Sponsors:   Cancer and Leukemia Group B;   National Cancer Institute (NCI);   Eastern Cooperative Oncology Group;   Southwest Oncology Group
Recruiting - verified March 2010

Conditions:   Kidney Disease;   Nephropathy;   Type 2 Diabetes
Interventions:   Drug: losartan;   Drug: lisinopril;   Drug: losartan
Sponsor:   Department of Veterans Affairs
Recruiting - verified March 2010

Condition:   Multiple Myeloma
Interventions:   Drug: Bortezomib;   Drug: Dexamethasone;   Drug: PD 0332991
Sponsor:   Pfizer
Recruiting - verified February 2010

Conditions:   Secondary Progressive Multiple Sclerosis;   Relapsing Forms of Multiple Sclerosis
Interventions:   Drug: natalizumab;   Other: standard of care
Sponsors:   Biogen Idec;   Elan Pharmaceuticals
Recruiting - verified February 2010

Condition:   Lung Cancer
Interventions:   Drug: carboplatin;   Drug: erlotinib hydrochloride;   Drug: paclitaxel albumin-stabilized nanoparticle formulation;   Radiation: radiation therapy
Sponsors:   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Leukemia
Interventions:   Drug: arsenic trioxide;   Drug: gemtuzumab ozogamicin;   Drug: mercaptopurine;   Drug: methotrexate;   Drug: tretinoin
Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Childhood Germ Cell Tumor;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Neuroblastoma;   Testicular Germ Cell Tumor;   Unspecified Adult Solid Tumor, Protocol Specific;   Unspecified Childhood Solid Tumor, Protocol Specific
Interventions:   Drug: busulfan;   Drug: carboplatin;   Drug: carmustine;   Drug: cyclophosphamide;   Drug: etoposide;   Drug: melphalan;   Drug: thiotepa;   Radiation: total-body irradiation
Sponsors:   Roswell Park Cancer Institute;   National Cancer Institute (NCI)
Recruiting - verified June 2009

Condition:   Lymphoma
Interventions:   Biological: pegfilgrastim;   Biological: rituximab;   Other: flow cytometry;   Other: immunohistochemistry staining method
Sponsors:   Roswell Park Cancer Institute;   National Cancer Institute (NCI)
Recruiting - verified February 2010

Condition:   Epilepsy
Interventions:   Drug: lacosamide;   Drug: lacosamide
Sponsor:   UCB, Inc.
Recruiting - verified March 2010

Condition:   Multiple Myeloma
Interventions:   Drug: bortezomib, thalidomide, and dexamethasone (VTD);   Drug: bortezomib and dexamethasone (VD);   Drug: bortezomib, melphalan and prednisone (VMP)
Sponsor:   Millennium Pharmaceuticals, Inc.
Recruiting - verified February 2010

Condition:   Epilepsy
Intervention:   Drug: Levetiracetam
Sponsor:   UCB, Inc.
Recruiting - verified February 2010

Conditions:   Sepsis;   Severe Sepsis;   Septic Shock
Interventions:   Procedure: Early Goal Directed Therapy (EGDT);   Procedure: Protocolized Standard Care (PSC);   Procedure: Usual Care (UC)
Sponsors:   National Institute of General Medical Sciences (NIGMS);   University of Pittsburgh
Recruiting - verified September 2008

Condition:   Colorectal Cancer
Interventions:   Biological: bevacizumab;   Biological: cetuximab;   Drug: fluorouracil;   Drug: irinotecan hydrochloride;   Drug: leucovorin calcium
Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI);   North Central Cancer Treatment Group;   Cancer and Leukemia Group B;   Eastern Cooperative Oncology Group;   NCIC Clinical Trials Group
Recruiting - verified March 2010

Condition:   Neuroblastoma
Interventions:   Drug: carboplatin;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: topotecan hydrochloride
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Prostate Cancer
Interventions:   Other: active surveillance;   Procedure: conventional surgery;   Procedure: quality-of-life assessment;   Radiation: brachytherapy;   Radiation: radiation therapy
Sponsors:   NCIC Clinical Trials Group;   National Cancer Institute (NCI);   Cancer and Leukemia Group B;   Eastern Cooperative Oncology Group;   Southwest Oncology Group
Recruiting - verified March 2010

Condition:   Lung Cancer
Interventions:   Procedure: thoracoscopic surgery;   Procedure: videothoracoscopy
Sponsors:   Cancer and Leukemia Group B;   National Cancer Institute (NCI);   Radiation Therapy Oncology Group;   American College of Surgeons;   Southwest Oncology Group
Recruiting - verified March 2010

Condition:   Lung Neoplasms
Intervention:   Drug: Pemetrexed
Sponsor:   Eli Lilly and Company
Recruiting - verified March 2010

Conditions:   Candidiasis;   Candida
Intervention:   Drug: anidulafungin
Sponsor:   Pfizer
Recruiting - verified March 2010

Condition:   Breast Cancer
Interventions:   Drug: Gemcitabine;   Drug: Sorafenib;   Drug: Placebo;   Drug: Capecitabine
Sponsors:   Accelerated Community Oncology Research Network;   Onyx Pharmaceuticals
Recruiting - verified March 2010

Condition:   Leukemia
Interventions:   Drug: mercaptopurine;   Drug: methotrexate;   Drug: tretinoin;   Other: clinical observation
Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Breast Cancer
Interventions:   Biological: Trastuzumab;   Drug: Lapatinib
Sponsor:   GlaxoSmithKline
Recruiting - verified March 2010

Condition:   Leukemia
Interventions:   Genetic: DNA ploidy analysis;   Genetic: chromosomal translocation analysis;   Genetic: fluorescence in situ hybridization;   Genetic: polymorphism analysis;   Other: immunologic technique;   Other: laboratory biomarker analysis;   Procedure: biopsy
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Cytomegalovirus Infections
Interventions:   Drug: Placebo;   Drug: Valganciclovir
Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified October 2009

Condition:   Lung Cancer
Interventions:   Genetic: chromogenic in situ hybridization;   Genetic: gene expression analysis;   Genetic: mutation analysis;   Genetic: polymerase chain reaction;   Genetic: polymorphism analysis;   Other: fluorescent antibody technique;   Other: immunohistochemistry staining method;   Other: laboratory biomarker analysis;   Other: matrix-assisted laser desorption/ionization time of flight mass spectrometry;   Other: study of socioeconomic and demographic variables;   Procedure: study of high risk factors
Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Epilepsies, Partial
Intervention:   Drug: Pregabalin
Sponsor:   Pfizer
Recruiting - verified March 2010

Condition:   Epilepsies, Partial
Interventions:   Drug: Placebo;   Drug: Pregabalin
Sponsor:   Pfizer
Recruiting - verified March 2010

Conditions:   Anemia;   Chronic Kidney Disease;   Kidney Disease
Interventions:   Drug: darbepoetin alfa QW;   Drug: darbepoetin alfa Q2W
Sponsor:   Amgen
Recruiting - verified March 2010

Condition:   Pulmonary Arterial Hypertension
Interventions:   Drug: bosentan;   Drug: bosentan and sildenafil combination
Sponsor:   Actelion
Recruiting - verified February 2010

Condition:   Prostate Cancer
Interventions:   Drug: docetaxel;   Drug: goserelin;   Drug: leuprolide acetate;   Procedure: conventional surgery
Sponsors:   Cancer and Leukemia Group B;   National Cancer Institute (NCI);   Eastern Cooperative Oncology Group;   NCIC Clinical Trials Group
Recruiting - verified March 2010

Condition:   HIV Infections
Intervention:   Drug: maraviroc
Sponsor:   Pfizer
Recruiting - verified February 2010

Condition:   Cancer (Solid Tumors)
Intervention:   Drug: BMS-690514
Sponsor:   Bristol-Myers Squibb
Recruiting - verified January 2010

Condition:   Unspecified Adult Solid Tumor, Protocol Specific
Interventions:   Procedure: cognitive assessment;   Procedure: psychosocial assessment and care
Sponsors:   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Leukemia
Interventions:   Biological: filgrastim;   Drug: busulfan;   Drug: cytarabine;   Drug: daunorubicin hydrochloride;   Drug: decitabine;   Drug: etoposide;   Genetic: cytogenetic analysis;   Procedure: autologous bone marrow transplantation;   Procedure: peripheral blood stem cell transplantation
Sponsors:   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
Recruiting - verified February 2010

Conditions:   Atrial Fibrillation;   Atrial Flutter
Interventions:   Drug: warfarin;   Drug: apixaban
Sponsor:   Bristol-Myers Squibb
Recruiting - verified October 2009

Condition:   Leukemia
Interventions:   Drug: cyclophosphamide;   Drug: cytarabine;   Drug: dexamethasone;   Drug: doxorubicin hydrochloride;   Drug: leucovorin calcium;   Drug: mercaptopurine;   Drug: methotrexate;   Drug: nelarabine;   Drug: pegaspargase;   Drug: thioguanine;   Drug: vincristine sulfate;   Radiation: radiation therapy
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Vesico-Ureteral Reflux;   Urinary Tract Infections
Interventions:   Drug: Trimethoprim-Sulfamethoxazole;   Drug: Placebo
Sponsor:   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified March 2010

Condition:   Brain and Central Nervous System Tumors
Interventions:   Biological: filgrastim;   Drug: carboplatin;   Drug: cisplatin;   Drug: cyclophosphamide;   Drug: isotretinoin;   Drug: vincristine sulfate;   Radiation: radiation therapy
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Brain Metastases From Non-small Cell Lung Cancer
Intervention:   Drug: HYCAMTIN, oral capsules
Sponsor:   GlaxoSmithKline
Recruiting - verified February 2010

Condition:   Breast Cancer
Interventions:   Drug: fulvestrant;   Drug: lapatinib ditosylate;   Other: placebo
Sponsors:   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Esophageal Cancer
Interventions:   Biological: cetuximab;   Drug: cisplatin;   Drug: epirubicin hydrochloride;   Drug: fluorouracil;   Drug: irinotecan hydrochloride;   Drug: leucovorin calcium;   Drug: oxaliplatin
Sponsors:   Cancer and Leukemia Group B;   National Cancer Institute (NCI);   Eastern Cooperative Oncology Group
Recruiting - verified June 2009

Condition:   Leukemia
Interventions:   Biological: filgrastim;   Drug: asparaginase;   Drug: cyclophosphamide;   Drug: cytarabine;   Drug: dexamethasone;   Drug: doxorubicin hydrochloride;   Drug: etoposide phosphate;   Drug: leucovorin calcium;   Drug: mercaptopurine;   Drug: methotrexate;   Drug: pegaspargase;   Drug: prednisone;   Drug: therapeutic hydrocortisone;   Drug: vincristine sulfate;   Radiation: radiation therapy
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Breast Cancer
Intervention:   Drug: chemotherapy
Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI);   Cancer and Leukemia Group B
Recruiting - verified March 2010

Conditions:   Graft Versus Host Disease;   Leukemia
Interventions:   Drug: methotrexate;   Drug: sirolimus;   Drug: tacrolimus
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Kidney Cancer
Interventions:   Biological: dactinomycin;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: vincristine sulfate;   Procedure: conventional surgery;   Radiation: radiation therapy
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Leukemia
Interventions:   Drug: asparaginase;   Drug: cytarabine;   Drug: daunorubicin hydrochloride;   Drug: etoposide;   Drug: gemtuzumab ozogamicin;   Drug: mitoxantrone hydrochloride
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Leukemia;   Myelodysplastic Syndromes
Interventions:   Drug: asparaginase;   Drug: cytarabine;   Drug: daunorubicin hydrochloride;   Drug: etoposide;   Drug: thioguanine
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Heart Failure;   Anemia;   Cardiovascular Disease;   Ventricular Dysfunction;   Congestive Heart Failure
Interventions:   Drug: Darbepoetin alfa;   Drug: Placebo
Sponsor:   Amgen
Recruiting - verified March 2010

Condition:   Sarcoma
Interventions:   Biological: dactinomycin;   Drug: cyclophosphamide;   Drug: irinotecan hydrochloride;   Drug: vincristine sulfate;   Radiation: radiation therapy
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   HIV-1
Intervention:   Drug: TMC125
Sponsor:   Tibotec Pharmaceuticals, Ireland
Recruiting - verified February 2010

Condition:   Epilepsies, Partial
Interventions:   Drug: Lyrica (pregabalin);   Drug: placebo
Sponsor:   Pfizer
Recruiting - verified March 2010

Condition:   Kidney Cancer
Interventions:   Biological: dactinomycin;   Drug: doxorubicin hydrochloride;   Drug: vincristine sulfate;   Procedure: conventional surgery;   Radiation: radiation therapy
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Childhood Malignant Fibrous Histiocytoma of Bone;   Sarcoma
Interventions:   Drug: doxorubicin hydrochloride;   Drug: ifosfamide;   Other: clinical observation;   Procedure: therapeutic conventional surgery;   Radiation: radiation therapy
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Brain and Central Nervous System Tumors
Interventions:   Drug: carboplatin;   Drug: cisplatin;   Drug: cyclophosphamide;   Drug: etoposide;   Drug: leucovorin calcium;   Drug: methotrexate;   Drug: thiotepa;   Drug: vincristine sulfate
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Kidney Cancer
Interventions:   Biological: dactinomycin;   Drug: carboplatin;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: irinotecan hydrochloride;   Drug: vincristine sulfate;   Procedure: conventional surgery;   Radiation: radiation therapy
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Kidney Cancer
Interventions:   Drug: sorafenib tosylate;   Drug: sunitinib malate;   Other: placebo
Sponsors:   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI);   Cancer and Leukemia Group B;   Southwest Oncology Group;   NCIC Clinical Trials Group
Recruiting - verified March 2010

Condition:   Lung Cancer
Interventions:   Biological: bevacizumab;   Drug: cisplatin;   Drug: docetaxel;   Drug: gemcitabine hydrochloride;   Drug: pemetrexed disodium;   Drug: vinorelbine ditartrate
Sponsors:   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI);   Southwest Oncology Group;   Cancer and Leukemia Group B;   NCIC Clinical Trials Group;   North Central Cancer Treatment Group
Recruiting - verified March 2010

Conditions:   Epilepsy;   Epilepsy, Generalized;   Epilepsy, Complex Partial;   Epilepsies, Partial;   Seizures
Interventions:   Drug: Diazepam;   Drug: Placebo
Sponsor:   King Pharmaceuticals Research and Development
Recruiting - verified March 2010

Condition:   Esophageal Cancer
Interventions:   Drug: cisplatin;   Drug: irinotecan hydrochloride;   Procedure: conventional surgery;   Procedure: neoadjuvant therapy;   Radiation: radiation therapy
Sponsors:   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
Recruiting - verified February 2010

Conditions:   Leukemia;   Myelodysplastic Syndromes
Interventions:   Drug: azacitidine;   Drug: entinostat
Sponsors:   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Prostate Cancer
Interventions:   Drug: antiandrogen therapy;   Drug: docetaxel
Sponsors:   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Lymphoma
Intervention:   Drug: bortezomib
Sponsors:   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
Recruiting - verified February 2010

Condition:   Breast Cancer
Interventions:   Drug: anastrozole;   Drug: chemotherapy;   Drug: exemestane;   Drug: letrozole;   Drug: tamoxifen citrate
Sponsors:   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI);   Southwest Oncology Group;   Cancer and Leukemia Group B;   American College of Surgeons;   North Central Cancer Treatment Group;   NCIC Clinical Trials Group;   National Surgical Adjuvant Breast and Bowel Project (NSABP)
Recruiting - verified March 2010

Condition:   Leukemia
Interventions:   Behavioral: compliance monitoring;   Drug: mercaptopurine;   Drug: methotrexate;   Other: study of socioeconomic and demographic variables
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Colorectal Cancer
Interventions:   Biological: bevacizumab;   Biological: cetuximab;   Drug: fluorouracil;   Drug: irinotecan hydrochloride;   Drug: leucovorin calcium;   Drug: oxaliplatin
Sponsors:   Cancer and Leukemia Group B;   National Cancer Institute (NCI);   Southwest Oncology Group
Recruiting - verified March 2010

Condition:   Lung Cancer
Interventions:   Drug: cisplatin;   Drug: pemetrexed disodium;   Procedure: adjuvant therapy;   Procedure: conventional surgery;   Procedure: neoadjuvant therapy
Sponsor:   Roswell Park Cancer Institute
Recruiting - verified February 2010

Condition:   Lymphoma
Interventions:   Biological: rituximab;   Drug: lenalidomide
Sponsors:   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Brain and Central Nervous System Tumors
Intervention:   Radiation: radiation therapy
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Colorectal Cancer
Interventions:   Biological: bevacizumab;   Drug: fluorouracil;   Drug: leucovorin calcium;   Drug: oxaliplatin;   Other: clinical observation
Sponsors:   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Metastatic Cancer;   Prostate Cancer
Interventions:   Drug: atrasentan hydrochloride;   Drug: docetaxel;   Drug: prednisone;   Other: placebo
Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Lymphoma
Interventions:   Biological: filgrastim;   Biological: rituximab;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: prednisone;   Drug: vincristine sulfate
Sponsors:   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Breast Cancer
Intervention:   Procedure: quality-of-life assessment
Sponsors:   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Lymphoma
Interventions:   Drug: CHOP regimen;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: prednisone;   Drug: vincristine sulfate;   Procedure: conventional surgery;   Radiation: radiation therapy
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Leukemia
Interventions:   Drug: cyclophosphamide;   Drug: cytarabine;   Drug: dexamethasone;   Drug: doxorubicin hydrochloride;   Drug: leucovorin calcium;   Drug: mercaptopurine;   Drug: methotrexate;   Drug: pegaspargase;   Drug: thioguanine;   Drug: vincristine sulfate;   Radiation: radiation therapy
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Leukemia
Interventions:   Biological: filgrastim;   Drug: cyclophosphamide;   Drug: cytarabine;   Drug: daunorubicin hydrochloride;   Drug: dexamethasone;   Drug: etoposide;   Drug: leucovorin calcium;   Drug: mercaptopurine;   Drug: methotrexate;   Drug: pegaspargase;   Drug: therapeutic hydrocortisone;   Drug: vincristine sulfate;   Radiation: radiation therapy
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Pneumonia, Staphylococcal
Interventions:   Drug: linezolid;   Drug: vancomycin
Sponsor:   Pfizer
Recruiting - verified February 2010

Condition:   Brain and Central Nervous System Tumors
Interventions:   Drug: cisplatin;   Drug: cyclophosphamide;   Drug: lomustine;   Drug: vincristine sulfate;   Radiation: radiation therapy
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Breast Cancer
Intervention:   Drug: exemestane
Sponsor:   NCIC Clinical Trials Group
Recruiting - verified March 2010

Condition:   Cancer
Interventions:   Genetic: cytogenetic analysis;   Genetic: mutation analysis;   Genetic: polymorphism analysis;   Other: questionnaire administration
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Metastatic Cancer;   Prostate Cancer
Interventions:   Drug: zoledronic acid;   Other: placebo
Sponsors:   Cancer and Leukemia Group B;   National Cancer Institute (NCI);   Southwest Oncology Group;   Eastern Cooperative Oncology Group;   NCIC Clinical Trials Group
Recruiting - verified March 2010

Condition:   Leukemia
Interventions:   Drug: cyclophosphamide;   Drug: cytarabine;   Drug: daunorubicin hydrochloride;   Drug: dexamethasone;   Drug: doxorubicin hydrochloride;   Drug: leucovorin calcium;   Drug: mercaptopurine;   Drug: methotrexate;   Drug: pegaspargase;   Drug: prednisone;   Drug: thioguanine;   Drug: vincristine sulfate;   Radiation: radiation therapy
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Sarcoma
Interventions:   Biological: dactinomycin;   Drug: cyclophosphamide;   Drug: vincristine sulfate;   Procedure: conventional surgery;   Radiation: radiation therapy
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Breast Cancer
Interventions:   Biological: filgrastim;   Biological: pegfilgrastim;   Biological: trastuzumab;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: paclitaxel
Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Breast Cancer;   Menopausal Symptoms;   Sexual Dysfunction and Infertility
Interventions:   Drug: cyclophosphamide;   Drug: goserelin
Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI);   Cancer and Leukemia Group B;   Eastern Cooperative Oncology Group;   International Breast Cancer Study Group
Recruiting - verified March 2010

Conditions:   Breast Cancer;   Psychosocial Effects of Cancer and Its Treatment
Interventions:   Procedure: psychosocial assessment and care;   Procedure: quality-of-life assessment
Sponsors:   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Breast Cancer
Interventions:   Drug: exemestane;   Drug: tamoxifen citrate
Sponsors:   International Breast Cancer Study Group;   National Cancer Institute (NCI);   Breast International Group
Recruiting - verified March 2010

Condition:   Breast Cancer
Interventions:   Drug: exemestane;   Drug: tamoxifen citrate;   Drug: triptorelin;   Procedure: oophorectomy;   Radiation: radiation therapy
Sponsors:   International Breast Cancer Study Group;   National Cancer Institute (NCI);   Breast International Group;   Cancer and Leukemia Group B;   NCIC Clinical Trials Group;   North Central Cancer Treatment Group;   National Surgical Adjuvant Breast and Bowel Project (NSABP);   Southwest Oncology Group
Recruiting - verified March 2010

Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases
Interventions:   Biological: anti-thymocyte globulin;   Biological: graft-versus-tumor induction therapy;   Biological: sargramostim;   Biological: therapeutic allogeneic lymphocytes;   Drug: cyclophosphamide;   Drug: fludarabine phosphate;   Drug: methylprednisolone;   Drug: mycophenolate mofetil;   Drug: tacrolimus;   Procedure: allogeneic bone marrow transplantation;   Procedure: peripheral blood stem cell transplantation;   Procedure: umbilical cord blood transplantation
Sponsors:   Roswell Park Cancer Institute;   National Cancer Institute (NCI)
Recruiting - verified June 2009

Conditions:   Childhood Germ Cell Tumor;   Extragonadal Germ Cell Tumor;   Ovarian Cancer
Interventions:   Biological: bleomycin sulfate;   Drug: cisplatin;   Drug: etoposide;   Procedure: conventional surgery
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Leukemia;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases
Interventions:   Genetic: chromosomal translocation analysis;   Genetic: cytogenetic analysis
Sponsors:   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Breast Cancer
Interventions:   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: paclitaxel
Sponsors:   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Leukemia
Interventions:   Biological: filgrastim;   Drug: cyclophosphamide;   Drug: cytarabine;   Drug: etoposide;   Drug: imatinib mesylate;   Drug: methotrexate;   Drug: tacrolimus;   Radiation: radiation therapy
Sponsors:   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Neuroblastoma
Interventions:   Biological: aldesleukin;   Biological: monoclonal antibody Ch14.18;   Biological: sargramostim;   Drug: isotretinoin
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Sarcoma
Interventions:   Biological: dactinomycin;   Drug: busulfan;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: ifosfamide;   Drug: melphalan;   Drug: vincristine sulfate;   Procedure: autologous hematopoietic stem cell transplantation;   Procedure: conventional surgery;   Radiation: radiation therapy
Sponsors:   University Hospitals, Leicester;   National Cancer Institute (NCI);   Children's Cancer and Leukaemia Group;   Societe Francaise Oncologie Pediatrique;   European Organization for Research and Treatment of Cancer;   Gesellschaft fur Padiatrische Onkologie und Hamatologie - Germany;   Gesellschaft fur Padiatrische Onkologie und Hamatologie - Austria;   Swiss Group for Clinical Cancer Research;   EBMT Solid Tumors Working Party;   Children's Oncology Group
Recruiting - verified March 2010

Condition:   HIV Infections
Intervention:  
Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified May 2009

Condition:   Leukemia
Interventions:   Genetic: reverse transcriptase-polymerase chain reaction;   Other: flow cytometry
Sponsors:   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases;   Nonmalignant Neoplasm;   Unspecified Adult Solid Tumor, Protocol Specific;   Unspecified Childhood Solid Tumor, Protocol Specific
Interventions:   Biological: anti-thymocyte globulin;   Drug: busulfan;   Drug: carboplatin;   Drug: cyclophosphamide;   Drug: etoposide;   Drug: fludarabine phosphate;   Drug: melphalan;   Drug: thiotepa;   Radiation: total-body irradiation
Sponsor:   Roswell Park Cancer Institute
Recruiting - verified June 2009

Condition:   Breast Cancer
Interventions:   Drug: letrozole;   Other: placebo
Sponsors:   NCIC Clinical Trials Group;   National Cancer Institute (NCI);   North Central Cancer Treatment Group;   International Breast Cancer Study Group;   Eastern Cooperative Oncology Group;   Southwest Oncology Group;   Cancer and Leukemia Group B;   European Organization for Research and Treatment of Cancer
Recruiting - verified June 2009